• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 4. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Recent Advances in the Study of 710943-26-3 and 1H-indazol-6-ylmethanamine in Chemical Biology and Pharmaceutical Research

The chemical compound with the identifier 710943-26-3 and the product name 1H-indazol-6-ylmethanamine have recently garnered significant attention in the field of chemical biology and pharmaceutical research. These molecules are of particular interest due to their potential applications in drug discovery and development, especially in the context of kinase inhibition and targeted cancer therapies. This research brief aims to provide an overview of the latest findings related to these compounds, highlighting their structural properties, biological activities, and therapeutic potential.

Recent studies have focused on the synthesis and characterization of 710943-26-3, a small molecule inhibitor that exhibits high selectivity for specific kinase targets. The compound's unique chemical structure, which includes the 1H-indazol-6-ylmethanamine moiety, has been shown to play a critical role in its binding affinity and inhibitory activity. Researchers have employed advanced techniques such as X-ray crystallography and molecular docking to elucidate the precise interactions between 710943-26-3 and its target proteins, providing valuable insights for the design of next-generation kinase inhibitors.

In addition to its kinase inhibitory properties, 1H-indazol-6-ylmethanamine has been investigated for its potential as a building block in the synthesis of novel pharmaceutical agents. Its versatility as a chemical scaffold allows for the introduction of various functional groups, enabling the development of compounds with tailored biological activities. Recent publications have demonstrated the utility of this moiety in the creation of potent and selective inhibitors for a range of disease-relevant targets, including inflammatory and neurodegenerative disorders.

One of the most promising applications of 710943-26-3 and 1H-indazol-6-ylmethanamine is in the field of oncology. Preclinical studies have shown that derivatives of these compounds exhibit potent anti-proliferative effects against a variety of cancer cell lines, with minimal toxicity to normal cells. Mechanistic studies have revealed that these effects are mediated through the inhibition of key signaling pathways involved in cell growth and survival, such as the PI3K/AKT/mTOR cascade. These findings have spurred further investigation into the potential of these compounds as candidates for clinical development.

Despite the promising results, challenges remain in the optimization of 710943-26-3 and 1H-indazol-6-ylmethanamine-based therapeutics. Issues such as pharmacokinetic properties, bioavailability, and off-target effects need to be addressed to ensure their suitability for human use. Recent efforts have focused on structural modifications to improve these parameters, with some success in enhancing drug-like properties while maintaining therapeutic efficacy.

In conclusion, the ongoing research on 710943-26-3 and 1H-indazol-6-ylmethanamine underscores their potential as valuable tools in chemical biology and drug discovery. The insights gained from these studies not only advance our understanding of kinase inhibition and targeted therapies but also pave the way for the development of novel treatments for a range of diseases. Future research directions may include the exploration of combination therapies and the identification of biomarkers to predict patient response to these compounds.

• 267413-25-2(1H-indazol-5-ylmethanamine)
• 43120-31-6(4,6-Dimethyl-1H-indazole)
• 3176-63-4(4-Methyl-1H-indazole)
• 1776-37-0(5-Methyl-1H-indazole)
• 23938-97-8(2,7-dimethylcinnolino[5,4,3-cde]cinnoline)
• 267413-23-0((1H-Indazol-6-yl)methanamine dihydrochloride)
• 943845-79-2(6-(Aminomethyl)-1H-indazole Hydrochloride)
• 698-24-8(6-Methyl-1H-indazole)
• 944898-72-0(1H-indazol-4-ylmethanamine)
• 944904-20-5(1H-indazol-7-ylmethanamine)